AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03829553 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: 5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
Study NCT03735459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reminders and accountability questionnaires
Description: Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
Study NCT04092322 — intervention group
Intervention type: DEVICE
Intervention: Actical accelerometers (Philips Respironics)
Description: patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
Study NCT00741195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
Study NCT04092322 — intervention group
Intervention type: OTHER
Intervention: PASE
Description: Physical Activity Scale for Elderly
Study NCT01857076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass surgery
Description: Gastric bypass surgery performed laparoscopically
Study NCT01857076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ileal transposition with sleeve
Description: Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
Study NCT01857076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical
Description: The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
Study NCT03192501 — intervention group
Intervention type: DRUG
Intervention: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
Description: Choose appropriate targeted drugs according to NGS/IHC results.
Study NCT00637858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 5mg
Description: Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
Study NCT00637858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 15mg
Description: Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
Study NCT00637858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 30mg
Description: Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
Study NCT00637858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene capsules (non Lyc-o-mato) 15 mg
Description: Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
Study NCT00637858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
Study NCT04559633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive and behavioral therapy (CBT)
Description: The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work.
Study NCT01542255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 1 mg/m2 vinblastine given three times per week administered intravenously.
Study NCT01542255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
Study NCT01542255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
Study NCT00741195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
Study NCT03538444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
Study NCT03538444 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Participants will undergo procedures that mimic rTMS, but that are inactive.
Study NCT01231178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate beverage
Description: The dosage is 3x500ml daily
Study NCT01231178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control beverage
Description: The dosage is 3x500ml daily
Study NCT04860999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
Study NCT02381028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk and emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of human milk followed by emollient
Study NCT02381028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of emollient
Study NCT02381028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of emollient
Study NCT03374254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab solution for IV infusion Q3W
Study NCT03272217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg (flat dose) IV every 21 days
Study NCT03272217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV every 21 days
Study NCT03150576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
Study NCT03150576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Study NCT03150576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Study NCT03500172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Description: Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sirolimus
Description: Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT03990922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block with ropivacaine
Description: Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
Study NCT03990922 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral block with saline
Description: Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
Study NCT03990922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine
Description: Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study NCT03990922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Description: Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study NCT03088410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: neonatal 4 weeks prophylactic
Study NCT03088410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: neonatal 4 weeks prophylactic
Study NCT00513474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00513474 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study NCT00513474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00513474 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: total-body irradiation
Description: Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine
Description: Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: allopurinol
Description: Allopurinol per institutional guidelines
Study NCT01686633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol 200/25 mcg
Description: Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
Study NCT01686633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol 100/25 mcg
Description: Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
Study NCT01686633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100 mcg
Description: Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
Study NCT01074957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
Study NCT01074957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath-Stacking Technique
Description: An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
Study NCT01074957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
Study NCT01441310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel node navigation surgery
Description: Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
Study NCT03374254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: tablet orally BID at 30 or 45 mg depending upon DLT profile
Study NCT03374254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study NCT03374254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
Study NCT03500172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
Study NCT03374254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil [5-FU]
Description: 2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study NCT03374254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study NCT01847456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin as nasal spray
Study NCT01847456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05076825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Sliding
Description: Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
Study NCT05076825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
Study NCT00987272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Study NCT00987272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%
Study NCT00987272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% Vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT00987272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.1% Vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT02915432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg anti-PD-1 mAb JS001 Q2W
Description: This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment.
Study NCT02915432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 360 mg anti-PD-1 mAb JS001 Q3W
Description: Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
Study NCT02915432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 240mg anti-PD-1 mAb JS001 Q3W
Description: Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
Study NCT03936192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulphate 1500mg and meloxicam 15mg
Description: glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
Study NCT03936192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg
Description: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
Study NCT03936192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo administered once daily for 12 weeks.
Study NCT01786876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled SPD557
Description: A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
Study NCT01141972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.